Q3 EPS Forecast for Larimar Therapeutics Lifted by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research note issued on Thursday, August 14th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.33) per share for the quarter, up from their prior estimate of ($0.41). Wedbush has a “Outperform” rating and a $15.00 price objective on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.53) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.21) EPS and FY2029 earnings at $2.76 EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.06.

Other equities research analysts also recently issued research reports about the company. Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. JMP Securities dropped their target price on Larimar Therapeutics from $22.00 to $18.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Guggenheim restated a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $18.43.

Larimar Therapeutics Stock Down 5.9%

LRMR stock opened at $4.01 on Monday. The company has a market cap of $331.95 million, a P/E ratio of -2.57 and a beta of 0.93. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $9.50. The business has a fifty day moving average of $3.29 and a 200-day moving average of $2.77.

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in Larimar Therapeutics in the fourth quarter valued at about $25,000. Algert Global LLC bought a new stake in shares of Larimar Therapeutics in the fourth quarter worth about $47,000. Savant Capital LLC bought a new stake in shares of Larimar Therapeutics in the second quarter worth about $39,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Larimar Therapeutics in the second quarter worth about $44,000. Finally, Graham Capital Management L.P. bought a new stake in shares of Larimar Therapeutics in the fourth quarter worth about $54,000. Institutional investors own 91.92% of the company’s stock.

Insider Buying and Selling

In related news, Director James E. Flynn acquired 9,375,000 shares of the company’s stock in a transaction that occurred on Thursday, July 31st. The stock was acquired at an average price of $3.20 per share, for a total transaction of $30,000,000.00. Following the completion of the acquisition, the director owned 9,538,945 shares of the company’s stock, valued at $30,524,624. This trade represents a 5,718.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.50% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.